Oncology & Cancer
Ovarian cancer genetics unravelled
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.
Aug 14, 2018
0
83
News tagged with serous ovarian cancer
Oncology & Cancer
Crosstalk between fallopian tube, ovary may drive the spread of ovarian cancer
New research from the University of Illinois at Chicago shows that cancer cells in the fallopian tube affect normal chemical signaling between reproductive tissues and stimulate the release of norepinephrine, a small molecule ...
Oct 9, 2018
0
73
Oncology & Cancer
AI model may help predict ovarian cancer treatment outcomes
An artificial intelligence (AI) model may help predict clinical outcomes at the time of laparoscopic assessment for advanced high-grade serous ovarian cancer (HGSOC), according to a study presented at the Society of Gynecologic ...
Mar 25, 2022
0
10
Oncology & Cancer
Novel biomarker found in ovarian cancer patients can predict response to therapy
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...
Sep 20, 2018
0
60
Oncology & Cancer
Examining resistance to immunotherapy in ovarian cancer
A team at Memorial Sloan Kettering Cancer Center (MSK) has uncovered several mechanisms of immune escape that can help explain why ovarian cancers have been resistant to immunotherapy to date.
Dec 15, 2022
0
52
Medications
New drug combination found to be twice as effective for some ovarian cancer patients as next best treatment
A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a phase II study.
Jun 5, 2023
0
14
Oncology & Cancer
Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for ...
Feb 3, 2022
0
42
Oncology & Cancer
Case report: Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing
Researchers associated with SEngine Precision Medicine, a precision oncology company that matches patients to medicines based on their own tumor samples, have published a new case report showing a patient's remarkable response ...
May 24, 2023
0
3
Oncology & Cancer
PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free ...
Sep 28, 2019
0
6
Oncology & Cancer
Researcher helps define subtypes of ovarian cancer
In a new paper published in the journal Clinical Cancer Research, CUNY SPH Associate Professor Levi Waldron and colleagues resolved the long-standing controversy over how to define molecular subtypes of high-grade serous ...
Sep 5, 2018
0
0
